Open Access<p>Association of the Pretreatment Lung Immune Prognostic Index with Survival Outcomes in Advanced Hepatocellular Carcinoma Patients Treated with PD-1 Inhibitors</p>
Author(s) -
Shixue Chen,
Ziwei Huang,
Wangping Jia,
Haitao Tao,
Sujie Zhang,
Junxun Ma,
Zhefeng Liu,
Jinliang Wang,
Lijie Wang,
Pengfei Cui,
Zhibo Zhang,
Di Huang,
Zhaosu Wu,
Xuan Zheng,
Yi Hu
Publication year - 2020
Publication title -
journal of hepatocellular carcinoma
Language(s) - English
Resource type - Journals
ISSN - 2253-5969
DOI - 10.2147/jhc.s277453
Subject(s) - medicine , hazard ratio , gastroenterology , hepatocellular carcinoma , proportional hazards model , log rank test , confidence interval , surgery
At present, there are no validated biomarkers that can predict whether patients with advanced hepatocellular carcinoma (aHCC) are likely to benefit from anti-PD-1 therapy. We aimed to determine whether lung immune prognostic index (LIPI) is associated with outcomes in patients with aHCC treated with PD-1 inhibitors.